NXL04, a novel β-lactamase inhibitor with broad-spectrum activity;NXL104, un nouvel inhibiteur de β-lactamases à large spectre

Journal des Anti-Infectieux

Volumn 13, Issue 1, 2011, Pages 20-24

  Cattoir, V ^a,b  

^a CHU CÔTE DE NACRE   (France)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

AVE1330A; Cephalosporinase; CTX M; ESBL; KPC; NXL104; lactamase inhibitor

Indexed keywords

AVIBACTAM; BETA LACTAMASE; CARBAPENEMASE; CEFTAZIDIME; CEPHALOSPORIN; CEPHALOSPORINASE; EXTENDED SPECTRUM BETA LACTAMASE; METALLO BETA LACTAMASE; NOVEXEL; PENICILLINASE; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; ENTEROBACTERIACEAE; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; URINARY TRACT INFECTION;

EID: 79959818074     PISSN: 22106545     EISSN: 22106545     Source Type: Journal    
DOI: 10.1016/j.antinf.2010.12.003     Document Type: Article

References (13)

1. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000;406:775-81.
2. Hall BG, Barlow M. Revised Ambler classification of β-lactamases. J Antimicrob Chemother 2005;55:1050-1.
3. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 2010;23:160-201.
4. Bebrone C, Lassaux P, Vercheval L, et al. Current challenges in antimicrobial chemotherapy: focus on β-lactamase inhibition. Drugs 2010;70:651-79.
5. Stachyra T, Pechereau MC, Bruneau JM et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-β-lactam β-lactamase inhibitor. Antimicrob Agents Chemother 2010;54:5132-8.
6. Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam betalactamase inhibitor. J Antimicrob Chemother 2004;54:410-7.
7. Livermore DM, Mushtaq S, Warner M, et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J Antimicrob Chemother 2008;62:1053-6.
8. Stachyra T, Levasseur P, Pechereau MC, et al. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009;64:326-9.
9. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with β-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009;53:3599-601.
10. Lagacé-Wiens P, Simner P, Tailor F et al. Activity of ceftazidime (CAZ)/NXL-104 versus CAZ alone and other comparators against 2399 Gram-negative bacilli: results from CANWARD 2009. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, 12-15 Sept 2010.
11. Livermore DM, Mushtaq S, Warner M et al. Activity of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390-4.
12. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime + NXL104 against Pseudomonas aeruginosa and other nonfermenters. J Antimicrob Chemother 2010; 65:2376-81.
13. Mushtaq S, Warner M, Williams G, et al. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2010;65:1428-32.